Targeting Phosphatidylserine Synthesis for Tumor Cell Suppression in Esophageal Squamous Cell Carcinoma and Glioblastoma.

Yixuan Hu, Yaqi Cui, Zeqiong Xu, Duo Wu, Xiaochun Yu

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yixuan HuState Key Laboratory of Gene Expression, School of Life Sciences, Westlake University, Hangzhou 310030, China.ORCID 0009-0002-1303-9353

Yaqi CuiState Key Laboratory of Gene Expression, School of Life Sciences, Westlake University, Hangzhou 310030, China.

Zeqiong XuState Key Laboratory of Gene Expression, School of Life Sciences, Westlake University, Hangzhou 310030, China.

Duo WuState Key Laboratory of Gene Expression, School of Life Sciences, Westlake University, Hangzhou 310030, China.

Xiaochun YuState Key Laboratory of Gene Expression, School of Life Sciences, Westlake University, Hangzhou 310030, China.

Funding

National Natural Science Foundation of China 32090034

6 · The paper itself

Abstract

While altered lipid metabolism is a hallmark of cancer, specific phospholipid dependencies remain poorly defined. Here, we identify phosphatidylserine synthase 1 (PTDSS1) as a targetable metabolic vulnerability in esophageal squamous cell carcinoma (ESCC) and glioblastoma (GBM). Pharmacological inhibition of PTDSS1 selectively and potently suppresses tumor growth both in vitro and in vivo. Mechanistically, PTDSS1 blockade triggers a rapid collapse of cellular phosphatidylserine (PS) and phosphatidylethanolamine (PE) pools, fundamentally disrupting endoplasmic reticulum (ER) homeostasis. This targeted lipid depletion activates a PERK-mediated autophagic response that ultimately yields to apoptosis. Clinically, pan-cancer transcriptomic analysis links elevated

Indexed as

CDPdiacylglycerol-Serine O-PhosphatidyltransferaseEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaGlioblastomaPhosphatidylserinesAnimalsApoptosisAutophagyCell Line, TumorEndoplasmic ReticulumGene Expression Regulation, NeoplasticHumansLipid MetabolismMicePhosphatidylethanolaminesCDPdiacylglycerol-Serine O-PhosphatidyltransferasephosphatidylethanolaminePhosphatidylethanolaminesPhosphatidylserinesesophageal squamous cell carcinomaglioblastomalipid metabolismphosphatidylserinePTDSS1

Identifiers

PMID42511570

DOI10.3390/ijms27146226

PMCPMC13411466

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.